The Integration of Adriamycin into Combined Therapy Approaches

  • S. K. Carter
  • R. H. Blum
Conference paper

Abstract

The Division of Cancer Treatment of the NCI has sponsored clinical trials with adriamycin in the United States since 1970. Since that time the Cancer Therapy Evaluation Program of the DCT has accumulated data on over 2. 000 cases treated with the drug as a single agent against a variety of tumors. Much of this data has recently been reviewed (1).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    BLUM, R., CARTER, S.: Review of adriamycin - A new anticancer drug with significant clinical activity. Ann. Int. Med. 80: 249–259, 1974.PubMedGoogle Scholar
  2. 2.
    HOOGSTRATEN, B., GEORGE, S.: Adriamycin and combination chemotherapy in breast cancer: A Southwest Oncology Group Study. Proc. Amer. Assoc. Cancer Res. 15: 70, 1974 (abstr. 279).Google Scholar
  3. 3.
    ROSNER, D., DAO, T., HORTON, J. et al.: Randomized study of adriamycin (ADM) vs. combined therapy (FCP) vs. adrenalectomy (ADX) in breast cancer. Proc. Amer. Assoc. Cancer Res. 15: 63, 1974 (abstr. 252).Google Scholar
  4. 4.
    AHMANN, D., BISEL, H., HAHN, R. G.: Phase II evaluation of adriamycin (NSC 123127) as treatment for disseminated breast cancer. Proc. Amer. Assoc. Cancer Res. 15: 100, 1974 (abstr. 397).Google Scholar
  5. 5.
    BULL, J., TORMEY, D., FALKSON, G. et al.: A comparison of adriamycin and methotrexate in combination regimens for metastatic breast cancer. Proc. Amer. Assoc. Cancer Res. 15: 118, 1974 (abstr. 472).Google Scholar
  6. 6.
    BLUMENSCHEIN, G., GARDENAS, J., FREIREICH, E., GOTTLIEB, J.: FAC chemotherapy for breast cancer. Proc. Amer. Soc. Clin. Oncology 15: 193, 1974 (abstr. 839).Google Scholar
  7. 7.
    SALMON, S., JONES, S.: Chemotherapy of advanced breast cancer with a combination of adriamycin and cyclophosphamide. Proc. Amer. Assoc. Cancer Res. 15: 90, 1974 (abstr. 359).Google Scholar
  8. 8.
    BONADONNA, G., MONFARDINI, S., DE LENA, M. et al.: Clinical trials with adriamycin. Results of a. three year study. In International Symposium on Adriamycin, edited by CARTER, S. K., DI MARCO, A., GHIONE, M. et al., New York, Springer-Verlag, 1972, pp 139–152.Google Scholar
  9. 9.
    KRAKOFF, I. H.: Adriamycin in adults with neoplastic disease. In International Symposium on Adriamycin, edited by CARTER, S. K., DI MARCO, A., GHIONE, M. et al. New York, Springer-Verlag, 1972, pp. 165–167.Google Scholar
  10. 10.
    TAN, C., ETCUBANAS, E., WOLLNER, N. et al.: Adriamycin in children acute leukemia, and other neoplastic disease. In International Symposium on Adriamycin, edited by CARTER, S. K., DI MARCO, A., GHIONE, M. et al.: New York, Springer-Verlag, 1972, pp 204–212.Google Scholar
  11. 11.
    TAN, C., ETCUBANAS, E., WOLLNER, N. et al.: Adriamycin, an antitumor antibiotic in the treatment of neoplastic disease. Cancer 32: 9–17, 1973.PubMedCrossRefGoogle Scholar
  12. 12.
    MIDDLEMAN, E., LUCE, J. K., FREI, E.: Clinical trials with adriamycin. Cancer 28: 844–850, 1971.PubMedCrossRefGoogle Scholar
  13. 13.
    O’BRYAN, R. M., LUCE, J. K., TALLEY, R. W. et al.: Phase II evaluation of adriamycin in human neoplasia. Cancer 32: 1–8, 1973.PubMedCrossRefGoogle Scholar
  14. 14.
    BENJAMIN, R. S., WIERNICK, P. H., BACHUR, N. R.: Adriamycin - efficacy, safety, and pharmacologic basis of a. single dose schedule (abstract no. 35). Annual Meeting, Amer. Soc. CIin. Oncology, Cancer Chemother. Rep. 57: 98, 1973.Google Scholar
  15. 15.
    OLDHAM, POMERY T. C.: Treatment of Ewing’s sarcoma with adriamycin (NSC 123127). Cancer Chemother. Rep. 56: 635–659, 1972.PubMedGoogle Scholar
  16. 16.
    WANG, J., CORTES, E. P., SINKS, L. et al.: Therapeutic effect and toxicity of adriamycin in patients with neoplastic diseases. Cancer 28: 837–843, 1971.PubMedCrossRefGoogle Scholar
  17. 17.
    CORTES, E. P., HOLLAND, J. J. et al.: Doxorubicin in disseminated osteosarcoma. JAMA 221: 1132–1138, 1972.CrossRefGoogle Scholar
  18. 18.
    GOTTLIEB, J. A., BAKER, L. H., QUAGLIANA, J. M. et al.: Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer 30: 1632–1638, 1972.PubMedCrossRefGoogle Scholar
  19. 19.
    GOLDSMITH, M. A., FRIEDMAN, M. A., CARTER, S. K.: Clinical Brochure, 5-(3, 3-dimethyl-1 -triazeno) imida. zole-4- carboxamide (DTIC, Die) NSC 45388, National Cancer Institute, Bethesda., 1972.Google Scholar
  20. 20.
    GOTTLIEB, J., BODEY, G., SINKOVICS, J. et al.: An effective new 4-drug combination (CY-VA-DIC) for metastatic sarcomas. Proc. Amer. Soc. Clin. Oncology 15: 162, 1974 (abstr. 713).Google Scholar
  21. 21.
    FRIEDMAN, M., CARTER, S.: The therapy of osteogenic sarcoma.: Current status and thoughts for the future. J. Surg. Oncology 4: 482–520, 1972.CrossRefGoogle Scholar
  22. 22.
    CORTES, E., HOLLAND, J., WANG, J. et al.: Adriamycin and amputation in primary osteogenic sarcoma. Proc. Amer. Soc. Clin. Oncology 15: 170, 1974 (abstr. 745).Google Scholar
  23. 23.
    SUTOW, W., SULLIVAN, P., FERNBACH, D.: Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. Proc. Amer. Assoc. Cancer Res. 15: 20, 1974 (abstr. 77).Google Scholar
  24. 24.
    WILBUR, J., ETCUBANAS, E., LONG, T. et al.: 4-drug therapy and irradiation in primary and metastatic osteogenic sarcoma. Proc. Amer. Soc. Clin. Oncology 15: 188, 1974 (abstr. 816).Google Scholar
  25. 25.
    SELAWRY, O. S.: Monochemotherapy of bronchogenic carcinoma with special reference to cell type. Cancer Chemother. Rep. (part 3) 4: 177–188, 1973.Google Scholar
  26. 26.
    SELAWRY, O. S., HANSEN, H. H.: Lung cancer, In Cancer Medicine, edited by HOLLAND, J. F., FREI, E. Philadelphia., Lea and Fibiger, 1973, pp 1473–1518.Google Scholar
  27. 27.
    GREEN, R. A., HUMPHREY, E., CLOSE, H. et al.: Alkylating agents in bronchogenic carcinoma. Amer. J. Med. 46: 516–525, 1969.PubMedCrossRefGoogle Scholar
  28. 28.
    KREYBERG, L.: Comments on the histological typing of lung -tumors. Acta Path. Microbiol. Scand (Section A) 79: 409–422, 1971.Google Scholar
  29. 29.
    LIVINGSTON, R., BURGESS, M., GOTTLIEB, J. et al.: Bleomycin, adriamycin, CCNU, oncovin, and nitrogen mustard (BACON) in squamous cancer. Proc. Amer. Soc. Clin. Oncology 15: 173, 1974 (abstr. 756).Google Scholar
  30. 30.
    LOWENBRAUN, S.: Cycle-nonspecific preceding cycle-specific chemotherapy in metastatic lung cancer (CA). Proc. Amer. Soc. Clin. Oncology 15: 162, 1974 (abstr. 712).Google Scholar
  31. 31.
    CARTER, S. K.: The chemotherapeutic approach to cancer therapy: A quick overview. In Yearbook of Cancer, edited by CLARK, R. L., CUMLEY, R. W., Chica. go, Year Book Medical Publishers, 1972, pp 495–498.Google Scholar
  32. 32.
    BLUM, R. H., AGRE, K., CARTER, S. K.: A clinical review of bleomycin - A new antineoplastic agent. Cancer 32: 904–914, 1973.Google Scholar
  33. 33.
    CARBONE, P. P.: Non-Hodgkin’s lymphoma: Recent observations on natural history and intensive treatment. Cancer 30: 1511–1516, 1972.PubMedCrossRefGoogle Scholar
  34. 34.
    MELVEY, E., GOTTLIEB, J., COLTMAN, C., WILSON, H.: Treatment of non-Hodglcin’ s lymphoma, with hydroxy Id aunomyc in (adriamycin) combination chemotherapy. Proc. Amer. Soc. Clin. Oncology 15: 184, 1974 (abstr. 802).Google Scholar
  35. 35.
    SKARIN, A., ROSENTHAL, D., MOLONEY, W., FREI, A. III: Treatment of advanced non-Hodgkin’s lymphoma (NHL) with bleomycin (B), adriamycin (A), cyclophosphamide (C), vincristine (0) and prednisone (P) (BACOP). Proc. Amer. Assoc. Cancer Res. 15: 133, 1974 (abstr. 531).Google Scholar
  36. 36.
    MREDIE, K., BODEY, G., GUTTERMAN, J. et al.: Sequential a. driamycin-ara. -C (A-OAP) for remission induction (RI) of adult acute leukemia. (AAL). Proc. Amer. Assoc. Cancer Res. 15: 62, 1974 (abstr. 246).Google Scholar
  37. 37.
    LIVINGSTON, R. B., CARTER, S. K.: Single Agents in Cancer Chemotherapy, New York, IFl/Plenum, 1970.Google Scholar
  38. 38.
    GOTTLIEB, J. A., HILL, C. S., IBANEZ, M. L. et al.: Chemotherapy of thyroid cancer. Cancer 30: 848–853, 1972.PubMedCrossRefGoogle Scholar
  39. 39.
    FREI, E., LUCE, J. K., MIDDLEMAN, E.: Clinical trials of adriamycin. In International Symposium on Adriamycin, edited by CARTER, S. K., DI MARCO, A., GHIONE, M. et al.: New York, Springer-Verlag, 1972, pp 153–160.Google Scholar
  40. 40.
    BENJAMIN, R. S., HUFFMAN, D. H., WIERNIK, P. H. et al.: Pharmacokinetics and metabolism of adriamycin patients with hematologic neoplasms and other malignancies, (abstract no. 508). XIV Intern. Congr. of Hematology, Sao Paulo (Brazil), July 16–21, 1972.Google Scholar
  41. 41.
    LE FRAK, E. A., PITHA, J., ROSENHEIM, S. et al.: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32: 302–314, 1973.CrossRefGoogle Scholar
  42. 42.
    WITHAM, A. C.: Cardiomyopathy (myocardosis). Idopathic concentric hypertrophy and restrictive cardiomyopathy, In The Heart, Arteries and Veins, edited by Hurst JW, Loque RB. New York, McGRAW-HILL, 1970, pp 1212–1 217.Google Scholar
  43. 43.
    GILLADOGA, A. C., TAN, C., WOLLNER, N. et al.: Adriamycin cardiomyopathy: Diagnosis and management, case reports (abstract). Proc. Amer. Ass. Cancer Res. 14: 95, 1973.Google Scholar
  44. 44.
    REICHENBACH, D. D., BENDITT, E. P.: Myofibrillar degeneration: A response of myocardial injury. Arch. Path. 85: 189–199, 1968.PubMedGoogle Scholar
  45. 45.
    GOTTLIEB, J. A., LE FRAK, E. A., OBRYAN, R. M. et al.: Fatal adriamycin cardiomyopathy: Prevention by dose limitation (abstract). Proc. Afner. Ass. Cancer Res. 14: 88, 1973.Google Scholar
  46. 46.
    CORTES, E. P., LUTMAN, G., WANKA, J., PICKREN, J., HOLLAND, J. F.: Adriamycin cardiotoxicity in adults with cancer. Clin. Res. 21: 412, 1973.Google Scholar
  47. 47.
    GILLADOGA, A., TAN, C., PHILIPS, S. et al.: Cardiac status of 40 children receiving adriamycin (Adr) over 495 mgs/m2 and animal studies. Proc. Amer. Assoc. Cancer Res. 15: 107, 1974 (abstr. 427).Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1975

Authors and Affiliations

  • S. K. Carter
    • 1
  • R. H. Blum
    • 2
  1. 1.Division of Cancer TreatmentNational Cancer InstituteBethesdaUSA
  2. 2.Boston City HospitalBostonUSA

Personalised recommendations